Hansen Gwenn

Chief Scientific Officer

1 company

Strong

Trades Analyzed

12M Win Rate

84.6%

Avg 3M Return

+5.0%

Avg 12M Return

+29.4%

Hansen Gwenn is a Chief Scientific Officer at Nurix Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 12 sells.

Estimated insider holdings value: $1.9M based on current market prices.

Holdings by Company

NRIXApr 30, 2026

Current Shares117.0K

Value$1.92M

Net Activity-54,899

Bought: 0Sold: 54.9K

Showing 10 filings

Date	Ticker	Role	Type	Shares	Price	Value	Chg%	3M	12M
Apr 30, 2026	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	3,214	$16.65	$53,497.99	-2.6%	-	-
Jan 30, 2026	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	4,895	$16.60	$81,249.16	-2.8%	+1.1%	-
Oct 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	4,087	$12.80	$52,300.11	-5.1%	+39.8%	-
Jul 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	4,308	$12.01	$51,743.39	-5.9%	+0.2%	-
Apr 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	3,377	$11.50	$38,841.24	-5.2%	+3.1%	-
Jan 30, 2025	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	3,690	$19.85	$73,259.85	-3.2%	-42.4%	-17.5%
Oct 30, 2024	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	3,437	$24.31	$83,536.29	-6.4%	-18.7%	-46.9%
Jul 30, 2024	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	3,408	$20.67	$70,435.52	-7.0%	+27.3%	-42.8%
Apr 30, 2024	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	2,007	$12.04	$24,168.70	-4.8%	+76.8%	-4.1%
Jan 30, 2024	NRIX Nurix Therapeutics, Inc.	Chief Scientific Officer	Sale+OE	2,334	$7.99	$18,649.13	-6.0%	+56.1%	+145.9%